

1 **Dramatic resurgence of malaria after 7 years of intensive vector control interventions in**  
2 **Eastern Uganda**

3  
4 \*Moses R. Kanya<sup>1,2\*</sup>, Joaniter I. Nankabirwa<sup>1,2</sup>, Emmanuel Arinaitwe<sup>1</sup>, John Rek<sup>1,3</sup>, Maato  
5 Zedi<sup>1</sup>, Catherine Maiteki-Sebuguzi<sup>1,3</sup>, Jimmy Opigo<sup>3</sup>, Sarah G. Staedke<sup>4</sup>, Ambrose Oruni<sup>4</sup>,  
6 Martin J. Donnelly<sup>4</sup>, Bryan Greenhouse<sup>5</sup>, Jessica Briggs<sup>5</sup>, Paul J. Krezanoski<sup>5</sup>, Teun Bousema<sup>6</sup>,  
7 Philip J. Rosenthal<sup>5</sup>, Peter Olwoch<sup>1</sup>, Prasanna Jagannathan<sup>7</sup>, Isabel Rodriguez-Barraquer<sup>5</sup>,  
8 Grant Dorsey<sup>5</sup>

9  
10  
11 <sup>1</sup>Infectious Diseases Research Collaboration, Kampala, Uganda.

12 <sup>2</sup>School of Medicine, Makerere University Kampala, Uganda.

13 <sup>3</sup>National Malaria Control Division, Ministry of Health, Kampala, Uganda,

14 <sup>4</sup>Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, United  
15 Kingdom,

16 <sup>5</sup>Department of Medicine, University of California San Francisco, San Francisco, California,  
17 USA.

18 <sup>6</sup>Department of Medical Microbiology, Radboud University Medical Center, Netherlands

19 <sup>7</sup>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford  
20 University, USA.

21  
22 \*Corresponding author: Moses R. Kanya. Email: [mkanya@idrc-uganda.org](mailto:mkanya@idrc-uganda.org) Tel:

23 +256776520469

24 **Key words:** malaria, effective malaria control, resurgence, long-lasting insecticidal nets (LLINs),  
25 indoor residual spraying of insecticide (IRS), clothianidin, pirimiphos-methyl

26 **Short title:** Malaria resurgence despite intensive control interventions in Uganda

27 **Abstract**

28 **Background:** Tororo District, Uganda experienced a dramatic decrease in malaria burden from  
29 2015-19 following 5 years of indoor residual spraying (IRS) with carbamate (Bendiocarb) and  
30 then organophosphate (Actellic) insecticides. However, a marked resurgence occurred in 2020,  
31 which coincided with a change to a clothianidin-based IRS formulations (Fludora  
32 Fusion/SumiShield). To quantify the magnitude of the resurgence, investigate causes, and  
33 evaluate the impact of a shift back to IRS with Actellic in 2023, we assessed changes in malaria  
34 metrics in regions within and near Tororo District.

35 **Methods:** Malaria surveillance data from Nagongera Health Center, Tororo District was  
36 included from 2011-2023. In addition, a cohort of 667 residents from 84 houses was followed  
37 from August 2020 through September 2023 from an area bordering Tororo and neighboring  
38 Busia District, where IRS has never been implemented. Cohort participants underwent passive  
39 surveillance for clinical malaria and active surveillance for parasitemia every 28 days.  
40 Mosquitoes were collected in cohort households every 2 weeks using CDC light traps. Female  
41 *Anopheles* were speciated and tested for sporozoites and phenotypic insecticide resistance.  
42 Temporal comparisons of malaria metrics were stratified by geographic regions.

43 **Findings:** At Nagongera Health Center average monthly malaria cases varied from 419 prior to  
44 implementation of IRS; to 56 after 5 years of IRS with Bendiocarb and Actellic; to 1591 after the  
45 change in IRS to Fludora Fusion/SumiShield; to 155 after a change back to Actellic. Among  
46 cohort participants living away from the border in Tororo, malaria incidence increased over 8-  
47 fold (0.36 vs. 2.97 episodes per person year,  $p < 0.0001$ ) and parasite prevalence increased over  
48 4-fold (17% vs. 70%,  $p < 0.0001$ ) from 2021 to 2022 when Fludora Fusion/SumiShield was used.  
49 Incidence decreased almost 5-fold (2.97 vs. 0.70,  $p < 0.0001$ ) and prevalence decreased by 39%  
50 (70% vs. 43%,  $p < 0.0001$ ) after shifting back to Actellic. There was a similar pattern among  
51 those living near the border in Tororo, with increased incidence between 2021 and 2022 (0.93

52 vs. 2.40,  $p < 0.0001$ ) followed by a decrease after the change to Actellic (2.40 vs. 1.33,  $p < 0.001$ ).  
53 Among residents of Busia, malaria incidence did not change significantly over the 3 years of  
54 observation. Malaria resurgence in Tororo was temporally correlated with the replacement of  
55 *An. gambiae* s.s. by *An. funestus* as the primary vector, with a marked decrease in the density  
56 of *An. funestus* following the shift back to IRS with Actellic. In Busia, *An. gambiae* s.s. remained  
57 the primary vector throughout the observation period. Sporozoite rates were approximately 50%  
58 higher among *An. funestus* compared to the other common malaria vectors. Insecticide  
59 resistance phenotyping of *An. funestus* revealed high tolerance to clothianidin, but full  
60 susceptibility to Actellic.

61 **Conclusions:** A dramatic resurgence of malaria in Tororo was temporally associated with a  
62 change to clothianidin-based IRS formulations and emergence of *An. funestus* as the  
63 predominant vector. Malaria decreased after a shift back to IRS with Actellic. This study  
64 highlights the ability of malaria vectors to rapidly circumvent control efforts and the importance  
65 of high-quality surveillance systems to assess the impact of malaria control interventions and  
66 generate timely, actionable data.

67

68

## 69 **Introduction**

70 Between 2000 and 2015 it was estimated the incidence of malaria in Sub-Saharan Africa  
71 decreased by 40%, with the scale up of vector control interventions responsible for the majority  
72 of cases averted.(1) However, since 2015 progress has stalled and even reversed course in  
73 some of the highest burden countries of Africa.(2) Indeed, the global burden of malaria has  
74 become increasingly concentrated in Africa, which accounted for over 94% of cases and 96% of  
75 deaths in 2022.(2) Turning the tide on malaria will require a better understanding of the root  
76 causes of stalled progress, better use of local data to inform policy decision making, and a more  
77 flexible and targeted approach to control interventions.(3)

78

79 Uganda is emblematic of other high burden African countries, where progress in reducing the  
80 burden of malaria has been slow and difficult to sustain despite the scale up of proven control  
81 interventions. Uganda was the first country to implement universal distribution of free long-  
82 lasting insecticidal nets (LLINs) starting in 2014, with repeated campaigns every 3-4 years.  
83 Uganda also has one of the largest indoor residual spraying of insecticide (IRS) programs,  
84 focusing on selected high transmission districts using different formulations of insecticides  
85 rotated every few years. The success of this intensive approach to vector control has been well  
86 documented in Tororo District, a historically high transmission area of southeastern Uganda,  
87 where our group has been conducting comprehensive cohort-based malaria surveillance studies  
88 since 2011.(4) IRS was first implemented in Tororo District in December 2014, initially using a  
89 carbamate (Bendiocarb), then switching to an organophosphate (Actellic) in 2016. Comparing  
90 key malaria indicators measured from 2011-14, prior to IRS, with indicators in 2017-19, after two  
91 rounds of universal LLIN distribution and 5 years of sustained IRS, we documented a 500-fold  
92 decrease in malaria transmission intensity, a 60-fold decrease in the incidence of symptomatic  
93 malaria, and a 5-fold decrease in parasite prevalence among children 0.5-10 years of age.(5) In  
94 addition, over this time frame there was a marked shift in the predominant vector species from

95 *An. gambiae* s.s. to *An. arabiensis*. However, following a change to clothianidin-based  
96 formulations of IRS in 2019-20, a marked resurgence of malaria cases was documented using  
97 health facility-based data from 5 districts of Uganda (including Tororo), reaching pre-IRS levels  
98 within 1-2 years.(6)

99

100 To better quantify the magnitude of the malaria resurgence in Tororo and to investigate potential  
101 causes, we compared temporal changes in malaria incidence, prevalence, and entomological  
102 measures between September 2020 and September 2023 in a cohort of 667 residents living in  
103 two areas within Tororo District and in neighboring Busia District, where IRS has never been  
104 implemented. In addition, we assessed changes after the formulation of IRS in Tororo District  
105 was shifted back to an organophosphate in March 2023.

106

## 107 **Methods**

### 108 ***Study setting and population level vector control interventions***

109 Our team has conducted a series of comprehensive cohort-based malaria surveillance studies  
110 (referred to as PRISM) in southeastern Uganda starting in October 2011 (Figure 1). Briefly, the  
111 “PRISM 1” study was conducted from October 2011 – September 2017 and the “PRISM 2”  
112 study conducted from October 2017 – October 2019 in Nagongera subcounty, Tororo District.(5)

113 The “PRISM Border Cohort” study (the focus of this report) was conducted from August 2020 –  
114 September 2023 in both Tororo District and neighboring Busia District. Tororo is historically a  
115 high malaria transmission district with an estimated entomological inoculation rate (EIR) of 310  
116 infective bites per person per year in 2011-12.(7) Prior to 2013, vector control in Tororo District  
117 was limited to the distribution of LLINs through antenatal care services. In November 2013,  
118 universal distribution of free LLINs was conducted as part of a national campaign, and similar  
119 campaigns were repeated in May 2017 and June 2020. All LLIN distribution campaigns in  
120 Tororo District utilized standard pyrethroid LLINs. IRS with the carbamate (Bendiocarb) was

121 introduced for the first time in Tororo in December 2014–January 2015, with additional rounds  
122 administered in June–July 2015 and November–December 2015. In June–July 2016, the IRS  
123 compound was changed to an organophosphate (Actellic), with repeated rounds in June–July  
124 2017, June–July 2018, and March–April 2019. The IRS program changed to clothianidin-based  
125 formulations in 2020, with Fludora Fusion (clothianidin + deltamethrin) administered in March  
126 2020 and March 2021, and SumiShield (clothianidin alone) administered in March 2022. In  
127 March 2023, a decision was made to shift back to IRS with Actellic in response to the  
128 resurgence of malaria. Busia is a high malaria transmission district bordering Tororo District to  
129 the south. As in Tororo, prior to 2013 vector control in Busia District was limited to targeted  
130 distribution of LLINs through antenatal care services. Universal distribution of free LLINs were  
131 conducted in Busia District in May 2013, May 2017, and December 2020. The first two LLINs  
132 distribution campaigns in Busia District utilized standard pyrethroid LLINs and the third  
133 campaign utilized LLINs containing deltamethrin plus piperonyl butoxide (PermaNet 3.0). IRS  
134 has never been implemented in Busia District.

135

### 136 ***Routine health facility-based malaria surveillance data***

137 To provide context, we illustrate continuous trends in disease burden from October 2011 –  
138 September 2023 at Nagongera Health Center IV, Tororo District (Figure 2). This health center is  
139 part of a national health facility-based malaria surveillance network that provides high-quality  
140 data to monitor geographic and temporal trends in malaria burden and assess the impact of  
141 population level control interventions.(6) Briefly, routine individual level data are collected from  
142 all patients who present to the outpatient departments, including the number of laboratory  
143 confirmed cases of malaria. Since November 2018, after mapping of the region, we have been  
144 able to estimate the incidence of malaria from a target area around Nagongera Health Center  
145 IV, defined as the number of cases of laboratory-confirmed malaria diagnosed at the health

146 center among patients residing in the target area, per unit time, divided by the total population of  
147 the target area.

148

### 149 ***Screening and enrollment of households into the cohort study***

150 Screening and enrollment of households and study participants was previously described.(8)

151 Briefly, in May 2020, all households in a contiguous study area including two sub-counties in

152 Tororo District and one sub-county in Busia District were enumerated and mapped using

153 handheld global positioning systems (Garmin e-Trex 10 GPS unit, Garmin International Inc.,

154 Olathe, KS) to provide a sampling frame for recruitment of households into the cohort study.

155 Households were enrolled from three distinct geographic regions (Figure 1). In August 2020, 20

156 households from Busia District located 1.9-3.2 km from the border with Tororo District and 30

157 households from Tororo district located 0.7-3.5 km from the border (referred to as Tororo, near

158 border) were enrolled. Preliminary data revealed that malaria burden was surprisingly similar

159 between houses in Busia District and those in Tororo near the border.(8) To capture more of a

160 gradient in transmission intensity, an additional 30 households from Tororo District located 5.5-

161 10.8 km from the border (referred to as Tororo, away from border) were enrolled in January

162 2021. Households were randomly selected from our enumeration list for screening and enrolled

163 if they met the following criteria: 1) having at least two members aged 5 years or younger; 2) no

164 more than 7 permanent residents currently residing; 3) no plans to move from the study

165 catchment area in the next 2 years; and 4) willingness to participate in entomological

166 surveillance studies. In March 2022, 4 households (3 from Busia and 1 from Tororo away from

167 the border) were enrolled to replace households that had been withdrawn from the cohort study.

168

### 169 ***Screening, enrollment and follow-up of cohort participants***

170 All permanent residents from enrolled households were screened and enrolled in the cohort

171 study if they met the following criteria: 1) the selected household was considered their primary

172 residence; 2) agreement to come to the study clinic for any febrile illness and scheduled routine  
173 visits; 3) agreement to avoid antimalarial medications outside the study; and 4) provision of  
174 written informed consent (for parent or guardian in the case of children). The cohort was  
175 dynamic, such that over the course of the study any permanent residents that joined a  
176 household were screened for enrollment. At enrollment, a baseline evaluation was conducted  
177 including a detailed medical history, focused physical examination, and blood collection by  
178 venipuncture for hemoglobin measurement, thick blood smear, and storage for future molecular  
179 studies. A household survey was conducted to collect information on characteristics of the  
180 household and LLIN ownership; all household members were provided access to an LLIN after  
181 the survey. A wealth index was generated for each household using principal components  
182 analysis based on common assets and categorized into tertiles. Cohort study participants were  
183 encouraged to come to a dedicated study clinic open 7 days per week for all their medical care.  
184 Routine visits were conducted every 4 weeks and included a standardized evaluation and  
185 collection of blood by finger prick/heel stick (if < 6 months of age) or venipuncture (if aged 6  
186 months and older) for thick blood smear, hemoglobin measurement (every 12 weeks), and  
187 storage for future molecular studies. Study participants found to have a fever (tympenic  
188 temperature > 38.0°C) or history of fever in the previous 24 hours at the time of any clinic visit  
189 had a thick blood smear read immediately. If the thick blood smear was positive by light  
190 microscopy, the patient was diagnosed with malaria and managed according to national  
191 guidelines. Study participants who missed their scheduled routine visits were visited at home  
192 and requested to come to the study clinic as soon as possible. All enrolled participants were  
193 followed through September 30th, 2023 unless they were prematurely withdrawn. Participants  
194 were withdrawn if they: 1) moved out of the cohort household; 2) were unable to be located for >  
195 4 months; 3) withdrew informed consent; or 4) were unable to comply with the study schedule  
196 and procedures.

197



198 **Laboratory evaluations**

199 Thick blood smears were stained with 2% Giemsa for 30 minutes and evaluated for the  
200 presence of asexual parasites. Parasite densities were calculated by counting the number of  
201 asexual parasites per 200 leukocytes (or per 500, if the count was less than 10 parasites per  
202 200 leukocytes), assuming a leukocyte count of 8,000/ $\mu$ L. A thick blood smear was considered  
203 negative if examination of 100 high power fields revealed no asexual parasites. For quality  
204 control, all slides were read by a second microscopist, and a third reviewer settled any  
205 discrepant readings. Quantitative PCR (qPCR) was performed at the time of enrollment, at each  
206 routine visit (every 4 weeks), and when malaria was diagnosed. At each of these time points,  
207 DNA was extracted from approximately 200  $\mu$ L of whole blood using Qiagen spin columns, and  
208 extraction products were tested for the presence and quantity of *P. falciparum* DNA using a  
209 highly sensitive qPCR assay targeting the multicopy conserved var gene acidic terminal  
210 sequence with a lower limit of detection of 50 parasite/mL.(9)

211

212 **Entomological surveillance**

213 Mosquito collections were conducted every 2 weeks in all rooms of study houses where cohort  
214 study participants slept using CDC light traps positioned 1 m above the floor (Model 512; John  
215 W. Hock Company, Gainesville, Florida, USA). Traps were set at 7 PM and contents collected  
216 at 7 AM the following morning. Entomology technicians assessed whether cohort study  
217 participants reported sleeping under an LLIN each morning when trap contents were collected.  
218 All female *Anopheles* were enumerated and identified taxonomically to species level based on  
219 morphological criteria according to established taxonomic keys.(10) Every 2 weeks, up to 30  
220 mosquitoes identified as from the *An. gambiae s.l.* complex from each of the 3 study sites were  
221 randomly selected for PCR analysis to distinguish *An. gambiae s.s.* from *An. arabiensis*.(11) All  
222 female *Anopheles* mosquitoes were stored in desiccant and up to 50 mosquitoes per CDC light  
223 trap collection were assessed for sporozoites using ELISA.(12)

224

225 ***Insecticide resistance phenotyping***

226 Insecticide resistance testing was performed using field caught mosquitoes collected from  
227 neighboring Mayuge district to compare the response of both *An. funestus s.l.* and *An. gambiae*  
228 *s.l.* to clothianidin and pirimiphos-methyl. Blood fed indoor-resting mosquitoes were collected in  
229 May 2023 using a Prokopack electric aspirator, kept for 3-4 days, and then made to lay eggs by  
230 forced-egg laying.(13) The F1 progeny were reared and then used for bioassays using CDC  
231 bottles for clothianidin and WHO tubes for pirimiphos-methyl at the standard diagnostic dose as  
232 per WHO protocol.(14) Mosquitoes were exposed at different times to assess the time response  
233 curve for both species and then kept for 5 days post exposure to clothianidin and 1 day post  
234 exposure to pirimiphos-methyl to assess delayed mortality.

235

236 ***Data analyses***

237 All data were collected using standardized case record forms and double-entered using  
238 Microsoft Access (Microsoft Corporation, Redmond, Washington, USA). Analyses were  
239 performed using Stata, version 14 (Stata Corporation, College Station, Texas, USA). The  
240 primary objective of the study was to compare temporal trends in key malaria metrics in the  
241 context of population level vector control interventions stratified by 3 geographic regions: 1)  
242 Tororo, away from border, 2) Tororo, near border, and 3) Busia (Figure 1). The incidence of  
243 symptomatic malaria was defined as the number of incident cases of malaria (fever plus a  
244 positive thick blood smear by microscopy) divided by the person time of observation. Episodes  
245 of malaria occurring within 10 days of a prior episode were not considered incident events. The  
246 prevalence of microscopic parasitemia was defined as the proportion of routine visits conducted  
247 every 4 weeks in which asexual parasites were detected by microscopy. When estimating the  
248 prevalence of microscopic or sub-microscopic parasitemia, samples that were positive by qPCR  
249 but negative by microscopy were added to the numerator. Vector density was defined as the

250 number of female *Anopheles* collected (stratified by species) divided by the number CDC light  
251 trap collections. The number of *An. gambiae s.s.* and *An. arabiensis* collected were estimated  
252 by multiplying the observed proportions using the subset tested with species PCR by the total  
253 number of *An. gambiae s.l.* collected stratified by each 2-week collection period and geographic  
254 region. Selected comparisons of measures of malaria incidence were made using mixed effects  
255 generalized linear models with a negative binomial regression family, with person time of  
256 observation included as an offset, and random effects at the level of the individual. Selected  
257 comparisons of measures of parasitemia at the time of routine visits were made using mixed  
258 effects generalized linear models with a Poisson family and random effects at the level of the  
259 individual. Selected comparisons of measures of vector density were made using negative  
260 binomial regression models with the number of CDC light trap collections included as an offset.  
261 For all comparisons, a p-value < 0.05 was considered statistically significant.

262

### 263 ***Ethics approval and informed consent***

264 Ethical approval was obtained from the Makerere University School of Medicine Research and  
265 Ethics Committee (REF 2019–134), the Uganda National Council for Science and Technology  
266 (HS 2700), the London School of Hygiene & Tropical Medicine Ethics Committee (17777), and  
267 the University of California, San Francisco Committee on Human Research (257790). Written  
268 informed consent was obtained for all participants prior to enrolment into the cohort study.

269

## 270 **Results**

### 271 ***Temporal changes in malaria burden from Nagongera Health Center***

272 Data on temporal changes in malaria burden from Nagongera Health Center (located in the  
273 interior of Tororo District) covering from approximately 3 years before until 9 years after the  
274 initiation of IRS are presented in Figure 2. From October 2011 – November 2014, prior to the  
275 implementation of IRS, an average of 419 laboratory confirmed cases were diagnosed each

276 month. After IRS was implemented, first with Bendiocarb (administered every 6 months)  
277 followed by Actellic (administered annually), there was a sharp decline in malaria burden,  
278 reaching an average of 56 cases per month and an incidence of 25 episodes per 1000 person  
279 years in the surrounding community from March 2019 – February 2020. After switching to  
280 annual rounds of IRS with clothianidin-based formulations in March 2020, malaria burden  
281 gradually began to increase. This increase accelerated after the 2nd round of Fludora Fusion in  
282 March 2021. From March 2022 – February 2023, following a round of SumiShield (the 3<sup>rd</sup> and  
283 final round of clothianidin-based IRS) malaria burden reached an average of 1591 cases per  
284 month and an incidence of 587 episodes per 1000 person years. Malaria burden declined  
285 sharply after switching back to IRS with Actellic in March 2023, reaching 155 cases and an  
286 incidence of 71 episodes per 1000 person years in September 2023.

287

### 288 ***Characteristics of cohort households and study participants***

289 A cohort study including 3 distinct geographic regions in Tororo and Busia districts was  
290 designed to further characterize the resurgence of malaria and explore potential causes.  
291 Characteristics of the households and cohort participants at the time of enrollment are  
292 presented in Table 1. Household characteristics unrelated to vector control interventions were  
293 similar across the three geographic regions, with the exception of household wealth, as a higher  
294 proportion of houses in Busia were in the poorest category compared to houses in Tororo. The  
295 proportion of houses that reported owning at least one LLIN at enrollment ranged from 30% in  
296 Busia to 74% in Tororo, away from border. Adequate LLIN coverage (defined as 1 LLIN per 2  
297 persons) was 19% and similarly low across the three geographic regions. All cohort households  
298 were provided LLINs by the study team following enrollment and 90% of household residents  
299 reported sleeping under an LLIN at the time of home assessments conducted every 2 weeks  
300 over the course of follow-up, with no significant differences between the three geographic  
301 regions. As expected, no households in Busia reported receiving IRS 12 months prior to

302 enrollment or during the course of the study. Household coverage for the 4 annual rounds of  
 303 IRS conducted in Tororo district from 2020 (assessed at enrollment) through 2023 was 90-100%  
 304 within Tororo, near border and 80-100% within Tororo, away from border.

305

306 **Table 1. Characteristics of households and cohort participants at enrolment**

Characteristic	Tororo District		Busia District
	Away from border	Near border	
<b>Household characteristics</b>			
Number of Households	31	30	23
Residents per household, median (range)	7 (4-7)	7 (4-7)	5 (3-7)
Type of housing construction, n (%)	Traditional	20 (64.5)	18 (60.0)
	Modern	11 (35.5)	12 (40.0)
Wealth category, n (%)	Poorest	5 (16.1)	7 (23.3)
	Middle	15 (48.4)	10 (33.3)
	Least poor	11 (35.5)	13 (43.3)
Number of rooms used for sleeping, median (range)	2 (1-3)	2 (1-4)	1 (1-3)
Number of sleeping spaces, median (range)	3 (2-4)	3 (2-4)	2 (2-6)
IRS in the last 12 months, n (%)	29 (93.6)	30 (100)	0
Households with at least 1 LLIN, n (%)	23 (74.2)	16 (53.3)	7 (30.4)
Households with 1 LLIN per 2 persons, n (%)	7 (22.6)	5 (16.7)	4 (17.4)
<b>Participant characteristics</b>			
Number of participants	246	235	186
Female gender, n (%)	146 (59.4)	125 (53.2)	98 (52.7)
Age in years, median (IQR)	11.1 (3.8-24.2)	9.2 (3.8-22.4)	8.5 (3.2-22.3)
Age categories, n (%)	< 5 years	83 (33.7)	81 (34.5)
	5-15 years	76 (30.9)	82 (34.9)
	> 15 years	87 (35.4)	72 (30.6)

307

308 ***Temporal changes in the incidence of malaria***

309 Monthly trends over the entire observation period in the incidence of malaria among cohort  
 310 participants of all ages are presented in Figure 3A stratified by geographic region. To allow for  
 311 direct comparisons over time and in relationship to rounds of IRS, malaria incidence (stratified  
 312 by geographic region and age categories) was quantified over 6-month time periods from April  
 313 2021 through September 2023 (Table 2). Among residents of all ages from Tororo, away from  
 314 border, the incidence of clinical malaria remained below 0.5 episodes per person year (PY) for  
 315 each of the first 7 months of observation from February-August 2021 before there was a sharp

316 increase, reaching over 4 episodes per PY in March 2022. The incidence remained above 2.2  
317 episodes per PY for all months from April 2022 until Actellic was sprayed in March 2023, after  
318 which there was a sharp decline, reaching 0.2 episodes per PY in September 2023 (Figure 3A).  
319 Comparing 6-month time periods from April–September following annual rounds of IRS, the  
320 incidence of malaria increased over 8-fold between 2021 and 2022 (0.36 vs. 2.97,  $p < 0.0001$ )  
321 corresponding to the second and third rounds of IRS with clothianidin-based formulations, then  
322 decreased almost 5-fold between 2022 and 2023 (2.97 vs. 0.70,  $p < 0.0001$ ) following the shift  
323 back to Actellic (Table 2). Among residents from Tororo, near border, the incidence of clinical  
324 malaria increased over 2.5-fold between April–September of 2021 and 2022 (0.93 vs. 2.40,  
325  $p < 0.0001$ ), then decreased almost 2-fold between 2022 and 2023 (2.40 vs. 1.33,  $p < 0.0001$ ).  
326 Among residents of Busia, the incidence of malaria between April–September did not change  
327 significantly from 2021 to 2022 to 2023. Across the 3 geographic regions, the incidence of  
328 malaria was between 3 and 4 times higher in children compared to adults, and the temporal  
329 patterns described above were similar across different age categories (Table 2). Despite the  
330 high burden of malaria in this study, only 4 of 2,266 episodes (0.2%) met WHO criteria for  
331 severe malaria: 2 cases of severe anemia ( $Hb < 5.0$  gm/dL) occurred in children with confirmed  
332 sickle cell disease, one of whom died; 1 case of severe anemia occurred in a 1 year old child  
333 who recovered; and 1 case of jaundice occurred in a 3 year old child who recovered.

334

335

336 **Table 2. Temporal changes in measures of malaria burden stratified by age categories and study site**

Study site	Age category	6-month time periods following the 2 <sup>nd</sup> round of Fludora Fusion in Tororo district				
		Apr 21 – Sep 21	Oct 21 – Mar 22	Apr 22 – Sep 22	Oct 22 – Mar 23	Apr 23 – Sep 23
<b>Incidence of clinical malaria = number of cases / person years of observation (episodes per person year)</b>						
Tororo, away from border	All ages	34/95.5 (0.36)	197/95.2 (2.07)	289/97.3 (2.97)	260/94.8 (2.74)	64/91.9 (0.70)
	< 5 years	15/30.8 (0.49)	83/28.4 (2.92)	114/28.4 (4.01)	106/25.5 (4.16)	13/20.2 (0.64)
	5-15 years	12/27.9 (0.43)	81/30.7 (2.64)	140/35.5 (3.94)	124/35.7 (3.47)	34/36.5 (0.93)
	> 15 years	7/36.7 (0.19)	33/36.1 (0.91)	35/33.3 (1.05)	30/33.6 (0.89)	17/35.2 (0.48)
Tororo, near border	All ages	89/95.5 (0.93)	132/95.4 (1.38)	219/91.3 (2.40)	216/95.3 (2.27)	123/92.6 (1.33)
	< 5 years	43/28.2 (1.53)	61/23.1 (2.64)	73/18.8 (3.89)	67/16.9 (3.96)	24/14.0 (1.72)
	5-15 years	38/35.2 (1.08)	58/40.2 (1.44)	116/42.3 (2.75)	123/47.6 (2.58)	78/47.4 (1.65)
	> 15 years	8/32.2 (0.25)	13/32.1 (0.40)	30/30.3 (0.99)	26/30.7 (0.85)	21/31.3 (0.67)
Busia	All ages	70/54.9 (1.27)	59/55.2 (1.07)	97/64.8 (1.50)	109/62.9 (1.73)	93/60.8 (1.53)
	< 5 years	30/16.6 (1.81)	18/15.1 (1.19)	30/15.8 (1.89)	30/13.5 (2.21)	21/11.5 (1.83)
	5-15 years	31/19.3 (1.61)	33/22.2 (1.49)	56/28.5 (1.96)	65/30.0 (2.17)	58/30.6 (1.90)
	> 15 years	9/19.1 (0.47)	8/17.9 (0.45)	11/20.4 (0.54)	14/19.4 (0.72)	14/18.7 (0.75)
<b>Prevalence of microscopic parasitemia at the time of routine visits performed every 4 weeks</b>						
Tororo, away from border	All ages	61/1177 (5.2%)	213/1255 (17.0%)	346/1209 (28.6%)	384/1250 (30.7%)	227/1145 (19.8%)
	< 5 years	9/374 (2.4%)	60/380 (15.8%)	97/351 (27.6%)	88/343 (25.7%)	29/255 (11.4%)
	5-15 years	33/341 (9.7%)	91/399 (22.8%)	157/444 (35.4%)	188/475 (39.6%)	143/451 (31.7%)
	> 15 years	19/462 (4.1%)	62/476 (13.0%)	92/414 (22.2%)	108/432 (25.0%)	55/439 (12.5%)
Tororo, near border	All ages	323/1325 (24.4%)	318/1139 (27.9%)	503/1266 (39.7%)	472/1143 (41.3%)	436/1259 (34.6%)
	< 5 years	63/387 (16.3%)	62/275 (22.5%)	98/262 (37.4%)	74/205 (36.1%)	49/188 (26.1%)
	5-15 years	203/492 (41.3%)	200/483 (41.4%)	307/587 (52.3%)	312/574 (54.4%)	291/654 (44.5%)
	> 15 years	57/446 (12.8%)	56/381 (14.7%)	98/417 (23.5%)	86/364 (23.6%)	96/417 (23.0%)
Busia	All ages	121/662 (18.3%)	145/794 (18.3%)	185/772 (24.0%)	195/858 (22.7%)	195/721 (27.0%)
	< 5 years	28/198 (14.1%)	22/221 (10.0%)	32/188 (17.0%)	32/187 (17.1%)	29/137 (21.2%)
	5-15 years	67/235 (28.5%)	94/319 (29.5%)	119/345 (34.5%)	117/406 (28.8%)	120/359 (33.4%)
	> 15 years	26/229 (11.4%)	29/254 (11.4%)	34/239 (14.2%)	46/265 (17.4%)	46/225 (20.4%)
<b>Prevalence of microscopic or sub-microscopic parasitemia at the time of routine visits performed every 4 weeks</b>						
Tororo, away from border	All ages	195/1177 (16.6%)	593/1255 (47.3%)	843/1209 (69.7%)	853/1250 (68.2%)	487/1145 (42.5%)
	< 5 years	42/374 (11.2%)	158/380 (41.6%)	238/351 (67.8%)	232/343 (67.6%)	79/255 (31.0%)
	5-15 years	79/341 (23.2%)	229/399 (57.4%)	339/444 (76.4%)	335/475 (70.5%)	215/451 (47.7%)
	> 15 years	74/462 (16.0%)	206/476 (43.3%)	266/414 (64.3%)	286/432 (66.2%)	193/439 (44.0%)
Tororo, near border	All ages	687/1325 (51.8%)	704/1139 (61.8%)	966/1266 (76.3%)	847/1143 (74.1%)	795/1259 (63.1%)
	< 5 years	141/387 (36.4%)	160/275 (58.2%)	200/262 (76.3%)	155/205 (75.6%)	99/188 (52.7%)
	5-15 years	329/492 (66.9%)	335/483 (69.4%)	487/587 (83.0%)	481/574 (83.8%)	464/654 (70.9%)
	> 15 years	217/446 (48.7%)	209/381 (54.9%)	279/417 (66.9%)	211/364 (58.0%)	232/417 (55.6%)
Busia	All ages	306/662 (46.2%)	356/794 (44.8%)	429/772 (55.6%)	478/858 (55.7%)	413/721 (57.3%)
	< 5 years	76/198 (38.4%)	73/221 (33.0%)	77/188 (41.0%)	81/187 (43.3%)	64/137 (46.7%)
	5-15 years	125/235 (53.2%)	180/319 (56.4%)	217/345 (62.9%)	249/406 (61.3%)	224/359 (62.4%)
	> 15 years	105/229 (45.9%)	103/254 (40.6%)	135/239 (56.5%)	148/265 (55.8%)	125/225 (55.6%)

### 338 ***Temporal changes in parasite prevalence***

339 Temporal changes in parasite prevalence mirrored those seen for incidence. Among residents  
340 of all ages from Tororo, away from border, the prevalence of microscopic parasitemia remained  
341 below 6% and the prevalence of microscopic or sub-microscopic parasitemia remained below  
342 18% for each of the first 7 months of observation (February-August 2021) before there was a  
343 sharp increase, reaching over 34% and 78%, respectively, in the year after the final round of  
344 clothianidin-based IRS was administered (Figure 3B and 3C). After IRS was changed back to  
345 Actellic in March 2023, there was a sharp decline in these measures, with parasitemia reaching  
346 13% and 30%, respectively. Comparing 6-month time periods from April–September following  
347 annual rounds of IRS, the prevalence of microscopic parasitemia increased over 5-fold (5% vs.  
348 29%,  $p<0.0001$ ) and the prevalence of microscopic or sub-microscopic parasitemia increased  
349 over 4-fold (17% vs 70%,  $p<0.0001$ ) between April-September of 2021 and April-September of  
350 2022. After spraying with Actellic, the prevalence of microscopic parasitemia decreased by 30%  
351 (29% vs. 20%,  $p<0.0001$ ) and the prevalence of microscopic or sub-microscopic parasitemia  
352 decreased by 39% (70% vs 43%,  $p<0.0001$ ). Among residents from Tororo, near border, the  
353 prevalence of microscopic parasitemia increased by 62% (24% vs. 40%,  $p<0.0001$ ) and the  
354 prevalence of microscopic or sub-microscopic parasitemia increased by 47% (52% vs. 76%,  
355  $p<0.0001$ ) between April-September of 2021 and April-September of 2022. After spraying with  
356 Actellic, the prevalence of microscopic parasitemia decreased by 13% (40% vs. 35%,  $p=0.04$ )  
357 and the prevalence of microscopic or sub-microscopic parasitemia decreased by 17% (76% vs.  
358 63%,  $p<0.0001$ ). Among residents from Busia, between April-September of 2021 and April-  
359 September of 2022 there were modest increases in the prevalence of microscopic parasitemia  
360 (18% vs. 24%,  $p=0.03$ ) and microscopic or sub-microscopic parasitemia (46% vs. 56%,  $p=0.03$ ),  
361 and, in contrast to the areas in Tororo receiving IRS with Actellic, remained similarly high in  
362 April-September of 2023. Across the 3 geographic regions, the prevalence of parasitemia was  
363 highest among children 5-15 years of age and the temporal patterns described above were  
364 similar across different age categories.



365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389

### **Temporal changes in entomological measures**

Among houses from Tororo, away from border, through December 2021 the predominant species was *An. arabiensis* (71% of female *Anopheles* collected) followed by *An. funestus* (14%) and *An. gambiae* s.s. (12%). After December 2021, *An. funestus* became the predominant species, a trend that continued until after IRS was shifted back to Actellic in March 2023, when the density of *An. funestus* decreased sharply (Figure 4A). Between mid-2021 and mid-2022, the density of *An. funestus* increased over 4-fold (0.2 vs 1.0 mosquitoes per collection,  $p < 0.0001$ ); this density then decreased over 10-fold (1.0 vs 0.08,  $p < 0.0001$ ) between mid-2022 and mid-2023. During these same 6-month time periods, the densities of *An. gambiae* s.s. and *An. arabiensis* decreased between 2021 and 2022, with no significant change from 2022 to 2023 (Table 3). Among houses from Tororo, near border, vector densities were initially more evenly distributed across the 3 major *Anopheles* species. After December 2021, *An. funestus* became the predominant species until after the round of IRS with Actellic in March 2023, although the decrease in *An. funestus* was not as sustained as in houses away from the border (Figure 4B, Table 3). In Busia, *An. gambiae* s.s. made up 73% of all female *Anopheles* collected and was the predominant species throughout the observation period, with the exception of June-August each year, when *An. funestus* was predominant (Figure 4C, Table 3).

Overall, sporozoite rates were approximately 50% higher among *An. funestus* (1.75%) compared to *An. arabiensis* (1.16%) and *An. gambiae* s.s. (1.12%), with sporozoite rates highest for *An. funestus* across all 3 geographic regions (Table 3). However, the study lacked precision to evaluate temporal trends in the proportion of mosquitoes infected with sporozoites.

390 **Table 3. Temporal changes in vector density stratified by Anopheles species and study site**

Study site	Anopheles species	6-month time periods following the 2 <sup>nd</sup> round of Fludora Fusion in Tororo district										Sporozoite rate (full study period)
		Apr 21 – Sep 21		Oct 21 – Mar 22		Apr 22 – Sep 22		Oct 22 – Mar 23		Apr 23 – Sep 23		
		N*	n (VD)*	N*	n (VD)*	N*	n (VD)*	N*	n (VD)*	N*	n (VD)*	
Tororo, away from border	<i>An. gambiae</i> s.s.		179 (0.2)		61 (0.09)		80 (0.1)		88 (0.1)		66 (0.09)	4/484 (0.83%)
	<i>An. arabiensis</i>	739	919 (1.2)	713	518 (0.7)	732	327 (0.4)	728	379 (0.5)	740	434 (0.6)	31/2818 (1.10%)
	<i>An. funestus</i>		170 (0.2)		419 (0.6)		749 (1.0)		757 (1.0)		56 (0.08)	43/2160 (1.99%)
	Other anopheles		54 (0.07)		32 (0.04)		18 (0.02)		21 (0.03)		21 (0.03)	1/155 (0.65%)
Tororo, near border	<i>An. gambiae</i> s.s.		769 (1.0)		276 (0.4)		604 (0.8)		222 (0.3)		298 (0.4)	35/5312 (0.66%)
	<i>An. arabiensis</i>	750	1577 (2.1)	763	832 (1.1)	744	604 (0.8)	749	446 (0.6)	747	842 (1.1)	86/7194 (1.20%)
	<i>An. funestus</i>		1313 (1.8)		1024 (1.3)		2570 (3.5)		1196 (1.6)		1154 (1.5)	125/7978 (1.57%)
	Other anopheles		60 (0.08)		23 (0.03)		80 (0.1)		28 (0.04)		153 (0.2)	3/482 (0.62%)
Busia	<i>An. gambiae</i> s.s.		2657 (6.7)		421 (1.1)		2042 (4.3)		728 (1.6)		1535 (3.3)	143/10500 (1.36%)
	<i>An. arabiensis</i>	397	259 (0.7)	395	27 (0.07)	472	320 (0.7)	463	92 (0.2)	472	128 (0.3)	13/1196 (1.09%)
	<i>An. funestus</i>		563 (1.4)		145 (0.4)		694 (1.5)		207 (0.4)		1107 (2.3)	62/2982 (2.08%)
	Other anopheles		19 (0.05)		5 (0.01)		16 (0.03)		12 (0.03)		27 (0.06)	2/114 (1.75%)

391 \* N = number of CDC LT collections, n = number of female anopheles mosquitoes collected, VD = vector density (n/N)

392

393 ***Insecticide resistance phenotyping***

394 Time response curves for *An. funestus s.l.* exposed to clothianidin and pirimiphos-methyl (active  
395 ingredient in Actellic) showed high resistance to clothianidin, but full susceptibility to pirimiphos-  
396 methyl (Figure 5). *An. gambiae s.l.* showed susceptibility to clothianidin even at reduced  
397 exposure times but mild tolerance to pirimiphos-methyl when exposure time was decreased.

398

399 **Discussion**

400 The combination of repeated universal LLIN distribution campaigns and sustained IRS has been  
401 associated with marked reductions in the burden of malaria at several historically holoendemic  
402 areas of Uganda, including Tororo District.(15) However, in 2020-21 malaria began to resurge in  
403 these areas following a change in IRS from an organophosphate to clothianidin-based  
404 formulations.(6) In this study, we quantified this resurgence and investigated potential causes in  
405 a cohort of residents of Tororo District, where IRS had been sustained since 2015, and  
406 neighboring Busia District, where IRS has never been implemented. In Tororo, resurgence of  
407 malaria increased approximately 18 months after the change to annual rounds of clothianidin-  
408 based IRS formulations, reaching a malaria incidence in children of over 4 episodes as  
409 compared to 0.5 episodes per year before the change, with over 75% of the population infected  
410 with malaria parasites. This resurgence was temporally correlated the emergence of *An.*  
411 *funestus* as the predominant malaria vector. In addition, *An. funestus* had a higher rate of  
412 infection with sporozoites compared to the other common malaria vectors and it exhibited high  
413 tolerance to clothianidin. Following a shift back to IRS with Actellic, the burden of malaria and  
414 the density of *An. funestus* declined sharply in Tororo. In contrast, in Busia district the burden of  
415 malaria remained high and relatively stable throughout this period, with *An. gambiae s.s.* the  
416 primary vector.

417

418 This study and others provide several lines of evidence to support a causal link between the  
419 change from an organophosphate (Actellic) to clothianidin-based (Fludora Fusion/SumiShield)

420 IRS formulations and the marked resurgence of malaria. First, the timing of the resurgence  
421 corresponded to a shift in active ingredient from pirimiphos-methyl to clothianidin-based  
422 formulations similar to what has been documented in 4 other districts of Uganda.(6) Second,  
423 the timing of the resurgence also corresponded with the emergence of *An. funestus*, which was  
424 found to have high tolerance to clothianidin and relatively high sporozoite rates, which likely  
425 contributed to a marked increase in transmission intensity. Third, the burden of malaria and  
426 density of *An. funestus* were sharply reduced when the formulation of IRS was shifted back to  
427 Actellic, a formulation for which *An. funestus* was found to be fully susceptible. Finally, just a few  
428 kilometers away in the neighboring district of Busia, malaria burden remained relatively  
429 unchanged, and the predominant vector was *An. gambiae s.s.*, consistent with historical reports  
430 from high transmission areas of Uganda.(16)

431  
432 Clothianidin is a neonicotinoid insecticide, one of 4 chemical classes prequalified for use in IRS  
433 by the WHO. The two most widely used clothianidin-based IRS formulations have been  
434 SumiShield™ (active ingredient clothianidin alone) and Fludora Fusion™ (active ingredients  
435 clothianidin combined with deltamethrin, a pyrethroid), which were prequalified by the WHO in  
436 2017 and 2018, respectively. In preparation for and following the subsequent rollout of  
437 clothianidin-based IRS formulations in sub-Saharan Africa, several field-based studies  
438 demonstrated broad susceptibility of major Anopheles vector species to clothianidin, with  
439 residual activity lasting up to 18 months.(17) In a study of wild pyrethroid resistant *An. gambiae*  
440 *s.l.* carried out in experimental huts in Benin from 2013-14, clothianidin caused high overall  
441 mortality rates across a range of wall surfaces.(18) In studies of insectary reared and wild  
442 collected mosquitoes conducted from 2016-17 across Africa, *An. gambiae s.l.* from 14 countries  
443 and *An. funestus* from 2 countries were widely susceptible to clothianidin.(19) Subsequent  
444 studies of field populations of common *Anopheles* species from Kenya, Benin, and Cote d'Ivoire  
445 also reported high mortality rates following exposure to clothianidin.(20, 21, 22, 23) It should be  
446 noted that clothianidin is slower acting than other commonly used insecticide classes, requiring

447 a longer holding period to fully assess post-exposure mortality.(18, 24, 25) Despite these  
448 encouraging reports, some recent data have suggested the existence of reduced susceptibility  
449 to clothianidin among African vectors, as reported in this study. In a rural area of Cameroon  
450 where neonicotinoids have been used for crop protection, field caught *An. gambiae* showed  
451 resistance to clothianidin.(26) In a study of laboratory susceptible and resistant laboratory  
452 strains using a variety of wall surfaces, the potency of clothianidin was lower against *An.*  
453 *funestus* compared to *An. gambiae*.(17) In a study from Cameroon, Malawi, Ghana, and  
454 Uganda, field collected *An. funestus* were broadly susceptible to clothianidin, however, possible  
455 cross-resistance was detected in mosquitoes with genetic mutations associated with metabolic  
456 resistance.(27) Importantly, in the only other study of the clinical impact of clothianidin-based  
457 IRS formulations, from Northern Zambia (where *An. funestus* is the primary vector) in 2019-20,  
458 IRS with Fludora Fusion had no impact on parasite prevalence, demonstrating, as in the current  
459 study, a lack of clinically relevant efficacy of the insecticide.(28)

460  
461 One of the most striking findings in this and previous studies conducted in Tororo District was  
462 the dramatic shift in *Anopheles* species predominance following the implementation of different  
463 formulations of IRS. Prior to the implementation of IRS, the primary vector was *An. gambiae* s.s.  
464 (74% of female *Anopheles* collected), followed by *An. arabiensis* (22%) and *An. funestus* (4%).  
465 After 5 years of IRS with Bendiocarb followed by Actellic, vector densities declined dramatically  
466 with *An. arabiensis* making up 99% of female *Anopheles* collected.(29) Entomologic  
467 surveillance was not conducted in the area from November 2019 – August 2020, corresponding  
468 to the period when IRS with Fludora Fusion was first implemented. However, just prior to the  
469 second round of Fludora Fusion, *An. arabiensis* remained the primary vector in houses away  
470 from the border in Tororo with a mix of *An. arabiensis* and *An. gambiae* s.s. predominating in  
471 houses near the border in Tororo and *An. gambiae* s.s. predominating in in houses on the Busia  
472 side of the border. Although low levels of *An. funestus* were detected at baseline in all 3  
473 geographic regions in this study, it was only just before the second round of clothianidin-based

474 IRS that this species emerged as the predominant vector in Tororo, corresponding to the  
475 dramatic resurgence of malaria. Interestingly, in houses away from the border in Tororo, *An.*  
476 *arabiensis* again became the predominant species after IRS was shifted back to Actellic,  
477 consistent with the trend previously seen when Actellic was used.

478  
479 *An. funestus* has emerged as an increasingly important malaria vector in many parts of sub-  
480 Saharan Africa. In a systematic review of studies from east and southern Africa, the primary  
481 vector shifted from *An. gambiae s.l.* between 2000 and 2010 to *An. funestus* between 2011 and  
482 2021.(30) In addition, several studies have reported higher infection rates among *An. funestus*  
483 relative to other *Anopheles* species.(30, 31, 32) *An. funestus* has rapidly developed insecticide  
484 resistance in many parts of Africa,(33, 34, 35, 36, 37) is highly anthropophilic, can survive  
485 longer than other vectors,(38) and may have the ability to take multiple blood meals within each  
486 gonotrophic cycle,(39) all factors that may have contributed to the increasing importance of this  
487 vector following the scale up vector control throughout Africa.

488  
489 Our prospective cohort study design allowed for a detailed description of the dynamics and  
490 magnitude of clinically relevant measures of the malaria resurgence. The rapid increase in the  
491 incidence of symptomatic malaria over a 6-9 month period was similar to historically high  
492 transmission areas of Uganda where IRS had been discontinued,(15, 40) suggesting that after  
493 the 2<sup>nd</sup> round of Fludora Fusion there was little or no impact, even in a setting of high reported  
494 utilization of LLINs. In addition, the peak incidence of malaria during the resurgence exceeded  
495 that in children enrolled in another cohort study prior to the implementation of IRS in Tororo  
496 District, an observation that was also documented using health facility-based data covering the  
497 period from 2011 through 2023 presented in Figure 1 of this study. Not only did the resurgence  
498 affect children, but malaria incidence also reached relatively high levels in adults. These findings  
499 suggest that the resurgence may have been compounded by a relative loss of naturally  
500 acquired immunity to malaria following an extended period when malaria had been well

501 controlled. Despite this suggestion of loss of immunity, there was no evidence from our cohort  
502 that there was a “excess” in the risk of severe forms of malaria, highlighting the importance of  
503 prompt and effective treatment available 7 days a week at our study clinic. However, a nearby  
504 hospital based study conducted during the malaria resurgence reported severe malaria affecting  
505 older children with unusual presentations including high risks of prostration, jaundice, severe  
506 anemia, and black water fever.(41)

507  
508 This study was not without limitations. First, we used an observational study design, with  
509 measures of impact based on comparisons of temporal trends between districts; a cluster  
510 randomized controlled trial would have better compared trends, but available resources did not  
511 allow this design. Second, there may have been other contributing factors to the resurgence that  
512 we did not fully explore, including the dynamics of host immunity. Third, we may have  
513 underestimated the overall burden of disease in the community during periods of resurgence,  
514 since our cohorts receive prompt treatment and close follow up. Fourth, entomological data  
515 were limited to CDC light traps, which do not provide direct measures of biting rates and  
516 information on the timing and location of mosquito-to-human transmission. Fifth, measures of  
517 insecticide susceptibility did not utilize mosquitoes collected in the study districts; although they  
518 were from a nearby district, susceptibility may have differed from that in Tororo District. Despite  
519 these limitations, this study benefited from the availability of prior comprehensive surveillance  
520 data collected from the area over an extended period, resulting in important scientific findings  
521 with significant policy implications.

522

## 523 **Conclusion**

524 Our findings show that resurgence of malaria in Tororo was temporally and geographically  
525 correlated with a change in IRS formulation from Actellic to Fludora Fusion and the unique  
526 emergence of *An. funestus* as the predominant vector. This unprecedented increase in malaria  
527 burden despite sustained and intense vector control combining repeated rounds of universal

528 LLIN distribution and IRS underscores the fragile nature of malaria control in Africa. Rotating  
529 IRS formulations has been promoted as a way to limit the selection of insecticide resistance, but  
530 in this case such a rotation was associated with a dramatic malaria resurgence in Uganda.  
531 Future changes in insecticides should take into consideration on-going surveillance that is  
532 comprehensive and includes clinical and entomological metrics, including vector species  
533 composition and insecticide resistance patterns. Surveillance data should also be timely and  
534 actionable, allowing for well-coordinated responses by policy makers. Indeed, the WHO Global  
535 Malaria Programme now encourages the use of multiple sources of data to better understand  
536 malaria risk at the sub-national level and to target interventions as part of its “High Burden High  
537 Impact” strategy.(42)

538

### 539 **Acknowledgements**

540 We thank all the study team members for successfully conducting the PRISM studies over the  
541 years and the Tororo and Busia district administrations for their support. We are grateful to the  
542 study participants who participated in this study and their families.

543

### 544 **Availability of data and materials**

545 Data from the cohort study and health facility-based surveillance will be made available through  
546 an established open-access clinical epidemiology database resource, ClinEpiDB.

547 <https://clinepidb.org/ce/app>

548

### 549 **Competing interests**

550 None

551

### 552 **Funding**

553 This project was funded by the US National Institutes of Health as part of the International  
554 Centers of Excellence in Malaria Research (ICEMR) program (U19AI089674). The funders



555 played no role in the design of the study; in the collection, analyses, and interpretation of data;  
556 in the writing of the manuscript; or in the decision to submit the manuscript for publication.

557

558 **Author's contributions**

559 **Conceptualization:** Joaniter I. Nankabirwa, Emmanuel Arinaitwe, Moses

560 R. Kamyra, Grant Dorsey.

561 **Data curation:** John Rek, Maato Zedi, Ambrose Oruni, Peter Olwoch, Jessica Briggs, Paul

562 Krezanoski, Bryan Greenhouse, Grant Dorsey.

563 **Formal analysis:** Grant Dorsey.

564 **Funding acquisition:** Moses R. Kamyra, Joaniter I. Nankabirwa, Grant Dorsey.

565 **Methodology:** Joaniter I. Nankabirwa, John Rek, Bryan Greenhouse, Ambrose Oruni, Moses

566 R. Kamyra, Grant Dorsey.

567 **Supervision:** Joaniter I. Nankabirwa, Emmanuel Arinaitwe, Moses R. Kamyra, Grant Dorsey.

568 **Writing – original draft:** Moses R. Kamyra, Joaniter I. Nankabirwa, Emmanuel Arinaitwe,

569 Ambrose Oruni, Grant Dorsey.

570 **Writing – review & editing:** all authors

571

572 **Figure Legend**

573 **Figure 1:** Map of eastern Uganda with an extract showing study sites.

574 **Figure 2:** Monthly trends in laboratory confirmed cases of malaria and malaria incidence from  
575 Nagongera Health Center. PY = person years.

576 **Figure 3:** Monthly trends in the incidence of clinical malaria, prevalence of microscopic  
577 parasitemia, and prevalence of microscopic or sub-microscopic parasitemia stratified by  
578 geographic regions. Vertical bars indicate rounds of IRS (Tororo District only): yellow = Fludora  
579 Fusion, purple = SumiShield, and orange = Actellic.

580 **Figure 4:** Monthly trends in the vector densities of common *Anopheles* species stratified by  
581 geographic regions. Vertical bars indicate rounds of IRS: yellow = Fludora Fusion, purple =  
582 SumiShield, and orange = Actellic.

583 **Figure 5:** Mortality of *An. gambiae s.l.* and *An. funestus* exposed to clothianidin and pirimiphos-  
584 methyl for varying durations.

585

586

587 **References**

- 588 1. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of  
589 malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. *Nature*.  
590 2015;526(7572):207-11.
- 591 2. World Health Organization. World malaria report 2023. Geneva: World Health  
592 Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.
- 593 3. World Health Organization. Global technical strategy for malaria 2016–2030, 2021  
594 update. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
- 595 4. Nankabirwa JI, Rek J, Arinaitwe E, Namuganga JF, Nsobya SL, Asua V, et al. East  
596 Africa International Center of Excellence for Malaria Research: Summary of Key Research  
597 Findings. *Am J Trop Med Hyg*. 2022;107(4\_Suppl):21-32.
- 598 5. Nankabirwa JI, Arinaitwe E, Rek J, Kilama M, Kizza T, Staedke SG, et al. Malaria  
599 Transmission, Infection, and Disease following Sustained Indoor Residual Spraying of  
600 Insecticide in Tororo, Uganda. *Am J Trop Med Hyg*. 2020;103(4):1525-33.
- 601 6. Epstein A, Maiteki-Sebuguzi C, Namuganga JF, Nankabirwa JI, Gonahasa S, Opigo J,  
602 et al. Resurgence of malaria in Uganda despite sustained indoor residual spraying and repeated  
603 long lasting insecticidal net distributions. *PLoS Global Public Health*.  
604 2022:doi.org/10.1371/journal.pgph.0000676.
- 605 7. Kanya MR, Arinaitwe E, Wanzira H, Katureebe A, Barusya C, Kigozi SP, et al. Malaria  
606 transmission, infection, and disease at three sites with varied transmission intensity in Uganda:  
607 implications for malaria control. *Am J Trop Med Hyg*. 2015;92(5):903-12.
- 608 8. Nankabirwa JI, Bousema T, Blanken SL, Rek J, Arinaitwe E, Greenhouse B, et al.  
609 Measures of malaria transmission, infection, and disease in an area bordering two districts with  
610 and without sustained indoor residual spraying of insecticide in Uganda. *PLoS ONE*.  
611 2022;17(12):e0279464.

- 612 9. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive  
613 detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS  
614 Med. 2015;12(3):e1001788.
- 615 10. Gillies MT, Coetzee M. A supplement to the Anophelinae of Africa South of the Sahara.  
616 Johannesburg: The South African Institute for Medical Research; 1987.
- 617 11. Scott JA, Brogdon WG, Collins FH. Identification of single specimens of the Anopheles  
618 gambiae complex by the polymerase chain reaction. Am J Trop Med Hyg. 1993;49(4):520-9.
- 619 12. Wirtz RA, Duncan JF, Njelesani EK, Schneider I, Brown AE, Oster CN, et al. ELISA  
620 method for detecting Plasmodium falciparum circumsporozoite antibody. Bull World Health  
621 Organ. 1989;67(5):535-42.
- 622 13. Morgan JC, Irving H, Okedi LM, Steven A, Wondji CS. Pyrethroid resistance in an  
623 Anopheles funestus population from Uganda. PLoS ONE. 2010;5(7):e11872.
- 624 14. World Health Organization. Manual for monitoring insecticide resistance in mosquito  
625 vectors and selecting appropriate interventions. Geneva: World Health Organization; 2022.  
626 Licence: CC BY-NC-SA 3.0 IGO.
- 627 15. Namuganga JF, Epstein A, Nankabirwa JI, Mpimbaza A, Kiggundu M, Sserwanga A, et  
628 al. The impact of stopping and starting indoor residual spraying on malaria burden in Uganda.  
629 Nat Commun. 2021;12(1):2635.
- 630 16. Yeka A, Gasasira A, Mpimbaza A, Achan J, Nankabirwa J, Nsohya S, et al. Malaria in  
631 Uganda: challenges to control on the long road to elimination: I. Epidemiology and current  
632 control efforts. Acta Trop. 2012;121(3):184-95.
- 633 17. Lees RS, Praulins G, Lissenden N, South A, Carson J, Brown F, et al. The Residual  
634 Efficacy of SumiShield 50WG and K-Othrine((R)) WG250 IRS Formulations Applied to Different  
635 Building Materials against Anopheles and Aedes Mosquitoes. Insects. 2022;13(2).
- 636 18. Ngufor C, Fongnikin A, Rowland M, N'Guessan R. Indoor residual spraying with a  
637 mixture of clothianidin (a neonicotinoid insecticide) and deltamethrin provides improved control

638 and long residual activity against pyrethroid resistant *Anopheles gambiae* s.l. in Southern Benin.  
639 PLoS ONE. 2017;12(12):e0189575.

640 19. Oxborough RM, Seyoum A, Yihdego Y, Dabire R, Gnanguenon V, Wat'senga F, et al.  
641 Susceptibility testing of *Anopheles malaria* vectors with the neonicotinoid insecticide  
642 clothianidin; results from 16 African countries, in preparation for indoor residual spraying with  
643 new insecticide formulations. *Malar J.* 2019;18(1):264.

644 20. Agumba S, Gimnig JE, Ogonda L, Ombok M, Kosgei J, Munga S, et al. Diagnostic dose  
645 determination and efficacy of chlorfenapyr and clothianidin insecticides against *Anopheles*  
646 *malaria* vector populations of western Kenya. *Malar J.* 2019;18(1):243.

647 21. Fongnikin A, Houeto N, Agbevo A, Odjo A, Syme T, N'Guessan R, et al. Efficacy of  
648 Fludora(R) Fusion (a mixture of deltamethrin and clothianidin) for indoor residual spraying  
649 against pyrethroid-resistant malaria vectors: laboratory and experimental hut evaluation. *Parasit*  
650 *Vectors.* 2020;13(1):466.

651 22. Kouassi BL, Edi C, Ouattara AF, Ekra AK, Bellai LG, Gouamene J, et al. Entomological  
652 monitoring data driving decision-making for appropriate and sustainable malaria vector control  
653 in Cote d'Ivoire. *Malar J.* 2023;22(1):14.

654 23. Odjo EM, Salako AS, Padonou GG, Yovogan B, Adoha CJ, Adjottin B, et al. What can  
655 be learned from the residual efficacy of three formulations of insecticides (pirimiphos-methyl,  
656 clothianidin and deltamethrin mixture, and clothianidin alone) in large-scale in community trial in  
657 North Benin, West Africa? *Malar J.* 2023;22(1):150.

658 24. Agossa FR, Padonou GG, Koukpo CZ, Zola-Sahossi J, Azondekon R, Akuoko OK, et al.  
659 Efficacy of a novel mode of action of an indoor residual spraying product, SumiShield(R) 50WG  
660 against susceptible and resistant populations of *Anopheles gambiae* (s.l.) in Benin, West Africa.  
661 *Parasit Vectors.* 2018;11(1):293.

662 25. Marti-Soler H, Maquina M, Opiyo M, Alafo C, Sherrard-Smith E, Malheia A, et al. Effect  
663 of wall type, delayed mortality and mosquito age on the residual efficacy of a clothianidin-based

664 indoor residual spray formulation (SumiShield 50WG) in southern Mozambique. PLoS ONE.  
665 2021;16(8):e0248604.

666 26. Fouet C, Ashu FA, Ambadiang MM, Tchappa W, Wondji CS, Kamdem C. Clothianidin-  
667 resistant *Anopheles gambiae* adult mosquitoes from Yaounde, Cameroon, display reduced  
668 susceptibility to SumiShield(R) 50WG, a neonicotinoid formulation for indoor residual spraying.  
669 BMC Infect Dis. 2024;24(1):133.

670 27. Assatse T, Tchouakui M, Mugenzi L, Menze B, Nguiffo-Nguete D, Tchappa W, et al.  
671 *Anopheles funestus* Populations across Africa Are Broadly Susceptible to Neonicotinoids but  
672 with Signals of Possible Cross-Resistance from the GSTe2 Gene. Trop Med Infect Dis.  
673 2023;8(5).

674 28. Ferriss E, Chaponda M, Muleba M, Kabuya JB, Lupiya JS, Riley C, et al. The Impact of  
675 Household and Community Indoor Residual Spray Coverage with Fludora Fusion in a High  
676 Malaria Transmission Setting in Northern Zambia. Am J Trop Med Hyg. 2023;109(2):248-57.

677 29. Musiime AK, Smith DL, Kilama M, Rek J, Arinaitwe E, Nankabirwa JI, et al. Impact of  
678 vector control interventions on malaria transmission intensity, outdoor vector biting rates and  
679 *Anopheles* mosquito species composition in Tororo, Uganda. Malar J. 2019;18(1):445.

680 30. Msugupakulya BJ, Urrio NH, Jumanne M, Ngowo HS, Selvaraj P, Okumu FO, et al.  
681 Changes in contributions of different *Anopheles* vector species to malaria transmission in east  
682 and southern Africa from 2000 to 2022. Parasit Vectors. 2023;16(1):408.

683 31. Akoton R, Sovegnon PM, Djihinto OY, Medjigbodo AA, Agonhossou R, Saizonou HM, et  
684 al. Vectorial competence, insecticide resistance in *Anopheles funestus* and operational  
685 implications for malaria vector control strategies in Benin Republic. Malar J. 2023;22(1):385.

686 32. Aschale Y, Getachew A, Yewhalaw D, De Cristofaro A, Sciarretta A, Atenafu G.  
687 Systematic review of sporozoite infection rate of *Anopheles* mosquitoes in Ethiopia, 2001-2021.  
688 Parasit Vectors. 2023;16(1):437.

- 689 33. Choi KS, Christian R, Nardini L, Wood OR, Agubuzo E, Muleba M, et al. Insecticide  
690 resistance and role in malaria transmission of *Anopheles funestus* populations from Zambia and  
691 Zimbabwe. *Parasit Vectors*. 2014;7:464.
- 692 34. Djouaka R, Riveron JM, Yessoufou A, Tchigossou G, Akoton R, Irving H, et al. Multiple  
693 insecticide resistance in an infected population of the malaria vector *Anopheles funestus* in  
694 Benin. *Parasit Vectors*. 2016;9:453.
- 695 35. Menze BD, Riveron JM, Ibrahim SS, Irving H, Antonio-Nkondjio C, Awono-Ambene PH,  
696 et al. Multiple Insecticide Resistance in the Malaria Vector *Anopheles funestus* from Northern  
697 Cameroon Is Mediated by Metabolic Resistance Alongside Potential Target Site Insensitivity  
698 Mutations. *PLoS ONE*. 2016;11(10):e0163261.
- 699 36. Mzilahowa T, Chiumia M, Mbewe RB, Uzalili VT, Luka-Banda M, Kutengule A, et al.  
700 Increasing insecticide resistance in *Anopheles funestus* and *Anopheles arabiensis* in Malawi,  
701 2011-2015. *Malar J*. 2016;15(1):563.
- 702 37. Pinda PG, Eichenberger C, Ngowo HS, Msaky DS, Abbasi S, Kihonda J, et al.  
703 Comparative assessment of insecticide resistance phenotypes in two major malaria vectors,  
704 *Anopheles funestus* and *Anopheles arabiensis* in south-eastern Tanzania. *Malar J*.  
705 2020;19(1):408.
- 706 38. Takken W, Verhulst NO. Host preferences of blood-feeding mosquitoes. *Annu Rev*  
707 *Entomol*. 2013;58:433-53.
- 708 39. Omondi S, Kosgei J, Musula G, Muchoki M, Abong'o B, Agumba S, et al. Late morning  
709 biting behaviour of *Anopheles funestus* is a risk factor for transmission in schools in Siaya,  
710 western Kenya. *Malar J*. 2023;22(1):366.
- 711 40. Raouf S, Mpimbaza A, Kigozi R, Sserwanga A, Rubahika D, Katamba H, et al.  
712 Resurgence of Malaria Following Discontinuation of Indoor Residual Spraying of Insecticide in  
713 an Area of Uganda With Previously High-Transmission Intensity. *Clin Infect Dis*.  
714 2017;65(3):453-60.

- 715 41. Namayanja C, Eregu EEI, Ongodia P, Okalebo CB, Okiror W, Okello F, et al. Unusual  
716 clinical spectra of childhood severe malaria during malaria epidemic in eastern Uganda: a  
717 prospective study. *Malar J.* 2023;22(1):169.
- 718 42. World Health Organization. *Malaria surveillance, monitoring & evaluation: a reference*  
719 *manual.* Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO..
- 720



Figure 1







Figure 2




## Incidence of clinical malaria

**A**

## Prevalence of microscopic parasitemia at the time of routine visits

**B**


## Prevalence of microscopic or sub-microscopic parasitemia at the time of routine visits

**C**


Month and year

— Tororo, away from border — Tororo, near border — Busia

Tororo, away from border



Tororo, near border



Busia

